BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, Seki H, Oguchi M, Taki S, Nambu Y. Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med. 2000;27:1778-1785. [PMID: 11189940 DOI: 10.1007/s002590000367] [Cited by in Crossref: 142] [Cited by in F6Publishing: 125] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Ikushima H, Dong L, Erasmus J, Allen P, Mcaleer MF, Zhuang Y, Sasaki R, Komaki R. Predictive Value of 18F-Fluorodeoxyglucose Uptake by Positron Emission Tomography for Non-Small Cell Lung Cancer Patients Treated with Radical Radiotherapy. JRR 2010;51:465-71. [DOI: 10.1269/jrr.10024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
2 Yang M, Lin Z, Xu Z, Li D, Lv W, Yang S, Liu Y, Cao Y, Cao Q, Jin H. Influx rate constant of 18F-FDG increases in metastatic lymph nodes of non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging 2020;47:1198-208. [PMID: 31974680 DOI: 10.1007/s00259-020-04682-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kaira K, Sunaga N, Ishizuka T, Shimizu K, Yamamoto N. The role of [¹⁸F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors. Cancer Imaging 2011;11:195-201. [PMID: 22138614 DOI: 10.1102/1470-7330.2011.0028] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
4 Park SG, Lee JH, Lee WA, Han KM. Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma. Nuclear Medicine and Biology 2012;39:1167-72. [DOI: 10.1016/j.nucmedbio.2012.07.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
5 Ozcan A, Shen SS, Zhai QJ, Truong LD. Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. Am J Clin Pathol 2007;128:245-54. [PMID: 17638658 DOI: 10.1309/HV6NJVRQKK4QHM9F] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
6 Meijer TW, Schuurbiers OC, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, Verhagen AF, Lok J, van der Heijden HF, Rademakers SE, Span PN, Bussink J. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer 2012;76:316-23. [PMID: 22153830 DOI: 10.1016/j.lungcan.2011.11.006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
7 Rendic S, Guengerich FP. Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 2010;11:4-84. [PMID: 20302566 DOI: 10.2174/138920010791110917] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
8 Vansteenkiste JF. Nodules, CT-scans and PET-scans: a good partnership. Lung Cancer 2004;45:29-30. [DOI: 10.1016/j.lungcan.2004.02.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
9 van Laarhoven HW, de Geus-Oei LF, Wiering B, Lok J, Rijpkema M, Kaanders JH, Krabbe PF, Ruers T, Punt CJ, van der Kogel AJ, Oyen WJ, Heerschap A. Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology. 2005;237:181-188. [PMID: 16183932 DOI: 10.1148/radiol.2371041397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
10 Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, Gurpide A, Zulueta JJ, Richter Echevarria JA, Perez Gracia JL. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2014;41:2058-65. [PMID: 24990403 DOI: 10.1007/s00259-014-2833-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 7.6] [Reference Citation Analysis]
11 Chang MC, Tsai SC, Lin WY. 18F-fluorodeoxyglucose uptake in different histological subtypes of nasopharyngeal carcinoma. J Laryngol Otol 2009;123:656-61. [PMID: 18845034 DOI: 10.1017/S002221510800368X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Choi H, Paeng JC, Kim DW, Lee JK, Park CM, Kang KW, Chung JK, Lee DS. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer 2013;79:242-7. [PMID: 23261227 DOI: 10.1016/j.lungcan.2012.11.021] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
13 Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study. Int J Cancer 2009;124:1152-60. [PMID: 19065657 DOI: 10.1002/ijc.24034] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
14 Colandrea M, Gilardi L, Travaini LL, Fracassi SLV, Funicelli L, Grana CM. 18F-FDG PET/CT in asymptomatic patients with COVID-19: the submerged iceberg surfaces. Jpn J Radiol 2020;38:1007-11. [PMID: 32577869 DOI: 10.1007/s11604-020-01006-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
15 Márquez Rodas I, de Miguel Díez J, Álvarez-sala JL. Positron Emission Tomography for the Study of Solitary Pulmonary Nodules. Archivos de Bronconeumología ((English Edition)) 2008;44:493-8. [DOI: 10.1016/s1579-2129(08)60089-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, Wei F, You J, Xu W, Ren X. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2020;47:1127-36. [PMID: 31502013 DOI: 10.1007/s00259-019-04500-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
17 Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci 2009;100:753-8. [PMID: 19141127 DOI: 10.1111/j.1349-7006.2008.01077.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
18 Tegnebratt T, Ruge E, Bader S, Ishii N, Aida S, Yoshimura Y, Ooi CH, Lu L, Mitsios N, Meresse V, Mulder J, Pawlak M, Venturi M, Tessier J, Stone-Elander S. Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. EJNMMI Res 2014;4:34. [PMID: 26116108 DOI: 10.1186/s13550-014-0034-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
19 van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, Rupa D, Pastorekova S, Stroobants S, Buell U, Lambin P, Vansteenkiste J, De Ruysscher D. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392-8. [PMID: 17512190 DOI: 10.1016/j.ejca.2007.03.027] [Cited by in Crossref: 155] [Cited by in F6Publishing: 141] [Article Influence: 11.1] [Reference Citation Analysis]
20 Minami K, Saito Y, Imamura H, Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002;38:51-7. [PMID: 12367793 DOI: 10.1016/s0169-5002(02)00108-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
21 Gao R, Wu X, Huang Z, Wang B, Li F, Xu H, Ran L. Anti-tumor effect of aloe-emodin on cervical cancer cells was associated with human papillomavirus E6/E7 and glucose metabolism. Onco Targets Ther 2019;12:3713-21. [PMID: 31190872 DOI: 10.2147/OTT.S182405] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Khandani AH, Funkhouser WK, Feins R, Socinski MA. Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancer. Ann Nucl Med 2009;23:595-7. [PMID: 19437096 DOI: 10.1007/s12149-009-0264-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
23 Higashi K, Matsunari I, Ueda Y, Ikeda R, Guo J, Oguchi M, Tonami H, Yamamoto I. Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med 2003;17:1-14. [DOI: 10.1007/bf02988253] [Cited by in Crossref: 36] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, Altorki NK. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84:177-181. [PMID: 17588407 DOI: 10.1016/j.athoracsur.2007.03.081] [Cited by in Crossref: 121] [Cited by in F6Publishing: 126] [Article Influence: 8.6] [Reference Citation Analysis]
25 Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, Vallières E, Wood DE. Relationship Between Non-small Cell Lung Cancer FDG Uptake at PET, Tumor Histology, and Ki-67 Proliferation Index. Journal of Thoracic Oncology 2008;3:971-8. [DOI: 10.1097/jto.0b013e31818307a7] [Cited by in Crossref: 104] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
26 Hong R, Lim SC. 18F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma. World J Gastroenterol 2012; 18(2): 168-174 [PMID: 22253523 DOI: 10.3748/wjg.v18.i2.168] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
27 Ozbudak IH, Shilo K, Tavora F, Rassaei N, Chu WS, Fukuoka J, Jen J, Travis WD, Franks TJ. Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. Mod Pathol 2009;22:633-8. [PMID: 19234439 DOI: 10.1038/modpathol.2009.6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
28 Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, Overgaard J. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 2008;122:2726-34. [PMID: 18351643 DOI: 10.1002/ijc.23449] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 6.5] [Reference Citation Analysis]
29 Marom EM, Sarvis S, Herndon JE, Patz EF. T1 Lung Cancers: Sensitivity of Diagnosis with Fluorodeoxyglucose PET. Radiology 2002;223:453-9. [DOI: 10.1148/radiol.2232011131] [Cited by in Crossref: 113] [Cited by in F6Publishing: 84] [Article Influence: 5.9] [Reference Citation Analysis]
30 Betzer O, Meir R, Dreifuss T, Shamalov K, Motiei M, Shwartz A, Baranes K, Cohen CJ, Shraga-Heled N, Ofir R, Yadid G, Popovtzer R. In-vitro Optimization of Nanoparticle-Cell Labeling Protocols for In-vivo Cell Tracking Applications. Sci Rep 2015;5:15400. [PMID: 26507853 DOI: 10.1038/srep15400] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
31 Nguyen XC, Lee WW, Chung JH, Park SY, Sung SW, Kim YK, So Y, Lee DS, Chung JK, Lee MC, Kim SE. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007;62:214-9. [PMID: 17239556 DOI: 10.1016/j.ejrad.2006.12.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 5.1] [Reference Citation Analysis]
32 Wood KA, Hoskin PJ, Saunders MI. Positron emission tomography in oncology: a review. Clin Oncol (R Coll Radiol) 2007;19:237-55. [PMID: 17433969 DOI: 10.1016/j.clon.2007.02.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
33 Kaira K, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Hayashi I, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. 18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: A clinicopathological study. European Journal of Radiology 2012;81:2423-9. [DOI: 10.1016/j.ejrad.2011.09.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
34 Tzror-azankot C, Betzer O, Sadan T, Motiei M, Rahimipour S, Atkins A, Popovtzer A, Popovtzer R. Glucose-Functionalized Liposomes for Reducing False Positives in Cancer Diagnosis. ACS Nano 2021;15:1301-9. [DOI: 10.1021/acsnano.0c08530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Goodwin J, Neugent ML, Lee SY, Choe JH, Choi H, Jenkins DMR, Ruthenborg RJ, Robinson MW, Jeong JY, Wake M, Abe H, Takeda N, Endo H, Inoue M, Xuan Z, Yoo H, Chen M, Ahn JM, Minna JD, Helke KL, Singh PK, Shackelford DB, Kim JW. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat Commun 2017;8:15503. [PMID: 28548087 DOI: 10.1038/ncomms15503] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 15.0] [Reference Citation Analysis]
36 Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol. 2003;58:215-221. [PMID: 12639527 DOI: 10.1016/s0009-9260(02)00477-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
37 Bozzetti F, Stanga Z. Does nutrition for cancer patients feed the tumour? A clinical perspective. Critical Reviews in Oncology/Hematology 2020;153:103061. [DOI: 10.1016/j.critrevonc.2020.103061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Luo XM, Zhou SH, Fan J. Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J Int Med Res 2010;38:1885-92. [PMID: 21226991 DOI: 10.1177/147323001003800601] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
39 Torizuka T, Nakamura F, Takekuma M, Kanno T, Ogusu T, Yoshikawa E, Okada H, Maeda M, Ouchi Y. FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer: . Nuclear Medicine Communications 2006;27:481-7. [DOI: 10.1097/00006231-200606000-00002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
40 Hagge RJ, Coleman RE. Positron emission tomography: lung cancer. Semin Roentgenol 2002;37:110-7. [PMID: 12134364 DOI: 10.1016/s0037-198x(02)80030-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Shon IH, O'doherty M, Maisey M. Positron emission tomography in lung cancer. Seminars in Nuclear Medicine 2002;32:240-71. [DOI: 10.1053/snuc.2002.126059] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
42 Zhu L, Yin G, Chen W, Li X, Yu X, Zhu X, Jiang W, Jia C, Chen P, Zhang Y, Lu D, Yu L, Li X, Xu W. Correlation between EGFR mutation status and F18 -fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma. Thorac Cancer 2019;10:659-64. [PMID: 30776196 DOI: 10.1111/1759-7714.12981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
43 Mahmood K, Naeem M, Rahimnajjad NA. Metformin: The hidden chronicles of a magic drug. European Journal of Internal Medicine 2013;24:20-6. [DOI: 10.1016/j.ejim.2012.10.011] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
44 Takamochi K, Mogushi K, Kawaji H, Imashimizu K, Fukui M, Oh S, Itoh M, Hayashizaki Y, Ko W, Akeboshi M, Suzuki K. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. PLoS One 2017;12:e0175622. [PMID: 28422979 DOI: 10.1371/journal.pone.0175622] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
45 Kaneko K, Sadashima S, Irie K, Hayashi A, Masunari S, Yoshida T, Omagari J. Assessment of FDG retention differences between the FDG-avid benign pulmonary lesion and primary lung cancer using dual-time-point FDG-PET imaging. Ann Nucl Med 2013;27:392-9. [DOI: 10.1007/s12149-013-0698-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
46 Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, Oriuchi N, Endo M, Ohde Y, Nakajima T, Yamamoto N. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer 2014;83:197-204. [PMID: 24365102 DOI: 10.1016/j.lungcan.2013.11.025] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 8.3] [Reference Citation Analysis]
47 Khandani AH, Whitney KD, Keller SM, Isasi CR, Donald Blaufox M. Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer. Nucl Med Commun. 2007;28:173-177. [PMID: 17264775 DOI: 10.1097/MNM.0b013e328013ebc5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
48 Furukawa T, Miyata Y, Kushitani K, Mimae T, Tsutani Y, Takeshima Y, Okada M. Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer. Jpn J Clin Oncol 2015;45:1154-61. [PMID: 26386467 DOI: 10.1093/jjco/hyv138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
49 Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW, Perrier ND. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid. 2004;14:806-812. [PMID: 15588375 DOI: 10.1089/thy.2004.14.806] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
50 Zhang B, Xie Z, Li B. The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: A meta-analysis. Gene 2019;689:76-83. [PMID: 30552981 DOI: 10.1016/j.gene.2018.12.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
51 Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009;30:594-601. [PMID: 19536037 DOI: 10.1097/MNM.0b013e32832cc295] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
52 Nguyen XC, So Y, Chung JH, Lee WW, Park SY, Kim SE. High correlations between primary tumours and loco-regional metastatic lymph nodes in non-small-cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2-F18-fluoro-D-glucose uptake. Eur J Cancer 2008;44:692-8. [PMID: 18314327 DOI: 10.1016/j.ejca.2008.02.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
53 Shimizu K, Maeda A, Yukawa T, Nojima Y, Saisho S, Okita R, Nakata M. Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma. World J Surg Oncol 2014;12:343. [PMID: 25392182 DOI: 10.1186/1477-7819-12-343] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
54 Dooms C, van Baardwijk A, Verbeken E, van Suylen RJ, Stroobants S, De Ruysscher D, Vansteenkiste J. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. J Thorac Oncol 2009;4:822-8. [PMID: 19487964 DOI: 10.1097/JTO.0b013e3181a97df7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
55 Stroobants S, Verschakelen J, Vansteenkiste J. Value of FDG-PET in the management of non-small cell lung cancer. European Journal of Radiology 2003;45:49-59. [DOI: 10.1016/s0720-048x(02)00282-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
56 Kaira K, Yamamoto N. Prognostic and predictive factors in resected non-small-cell lung cancer. Expert Opinion on Medical Diagnostics 2010;4:373-81. [DOI: 10.1517/17530059.2010.506214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
57 Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Kondo H, Nakajima T, Yamamoto N. Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma. Lung Cancer 2011;71:144-50. [PMID: 20646779 DOI: 10.1016/j.lungcan.2010.05.021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
58 Wang Y, Ma S, Dong M, Yao Y, Liu K, Zhou J. Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT. BMC Pulm Med 2015;15:20. [PMID: 25880540 DOI: 10.1186/s12890-015-0014-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
59 Ulger S, Demirci NY, Eroglu FN, Cengiz HH, Tunc M, Tatci E, Yilmaz U, Cetin E, Avci E, Cengiz M. High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy, independently of tumor size. J Cancer Res Clin Oncol 2014;140:495-502. [PMID: 24474555 DOI: 10.1007/s00432-014-1591-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
60 Kamiyama H, Sakamoto K, Niwa K, Ishiyama S, Takahashi M, Kojima Y, Goto M, Tomiki Y, Nakamichi I, Oh S, Suzuki K. Unusual False-Positive Mesenteric Lymph Nodes Detected by PET/CT in a Metastatic Survey of Lung Cancer. Case Rep Gastroenterol 2016;10:275-82. [PMID: 27462197 DOI: 10.1159/000446579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 Kaira K, Horie Y, Ayabe E, Murakami H, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol. 2010;5:460-465. [PMID: 20107421 DOI: 10.1097/jto.0b013e3181ce3e3c] [Cited by in Crossref: 68] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
62 Takahashi M, Momose T, Kameyama M, Ohtomo K. Abnormal accumulation of [18F]fluorodeoxyglucose in the aortic wall related to inflammatory changes: Three case reports. Ann Nucl Med 2006;20:361-4. [DOI: 10.1007/bf02987248] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
63 Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North Am 2007;45:21-43. [PMID: 17157622 DOI: 10.1016/j.rcl.2006.10.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
64 Wang Y, Yun Y, Wu B, Wen L, Wen M, Yang H, Zhao L, Liu W, Huang S, Wen N, Li Y. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription. Oncotarget 2016;7:47985-97. [PMID: 27351131 DOI: 10.18632/oncotarget.10103] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
65 Lee Y, Chung JH, Kim SE, Kim TJ, Lee KW. Adenosquamous carcinoma of the lung: CT, FDG PET, and clinicopathologic findings. Clin Nucl Med 2014;39:107-12. [PMID: 23751831 DOI: 10.1097/RLU.0b013e3182952c2d] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
66 Marini C, Ravera S, Buschiazzo A, Bianchi G, Orengo AM, Bruno S, Bottoni G, Emionite L, Pastorino F, Monteverde E, Garaboldi L, Martella R, Salani B, Maggi D, Ponzoni M, Fais F, Raffaghello L, Sambuceti G. Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt. Sci Rep 2016;6:25092. [PMID: 27121192 DOI: 10.1038/srep25092] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 9.8] [Reference Citation Analysis]
67 Bollineni VR, Kerner GS, Pruim J, Steenbakkers RJ, Wiegman EM, Koole MJ, de Groot EH, Willemsen AT, Luurtsema G, Widder J. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. J Nucl Med. 2013;54:1175-1180. [PMID: 23753185 DOI: 10.2967/jnumed.112.115014] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
68 Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J Nucl Med 2011;52:705-11. [PMID: 21498541 DOI: 10.2967/jnumed.111.087676] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
69 Okita R, Yukawa T, Nojima Y, Maeda A, Saisho S, Shimizu K, Nakata M. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer. Cancer Immunol Immunother 2016;65:499-509. [DOI: 10.1007/s00262-016-1814-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
70 Takada K, Toyokawa G, Okamoto T, Baba S, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Honda H, Oda Y, Maehara Y. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Med 2017;6:2552-61. [PMID: 28980429 DOI: 10.1002/cam4.1215] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
71 Ai B, Fu X, Liao Y. [The relationship of GLUT1 and lung cancer and its PET imaging]. Zhongguo Fei Ai Za Zhi 2010;13:165-7. [PMID: 20673512 DOI: 10.3779/j.issn.1009-3419.2010.02.17] [Reference Citation Analysis]
72 Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 2008;61:54-60. [PMID: 18191496 DOI: 10.1016/j.lungcan.2007.11.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
73 Chung J, Lee W, Park S, Choe G, Sung S, Chung J, Lee M, Kim S. FDG uptake and glucose transporter type 1 expression in lymph nodes of non-small cell lung cancer. European Journal of Surgical Oncology (EJSO) 2006;32:989-95. [DOI: 10.1016/j.ejso.2006.05.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
74 Skoura E, Datseris IE, Exarhos D, Chatziioannou S, Oikonomopoulos G, Samartzis A, Giannopoulou C, Syrigos KN. Clinical importance of [18F]fluorodeoxyglucose positron emission tomography/computed tomography in the management of patients with bronchoalveolar carcinoma: Role in the detection of recurrence. Oncol Lett 2013;5:1687-93. [PMID: 23761835 DOI: 10.3892/ol.2013.1257] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Yin Q, Hung SC, Wang L, Lin W, Fielding JR, Rathmell WK, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D. Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study. Sci Rep 2017;7:43356. [PMID: 28256615 DOI: 10.1038/srep43356] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
76 Binderup T, Knigge UP, Federspiel B, Sommer P, Hasselby JP, Loft A, Kjaer A. Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation. Diagnostics (Basel) 2013;3:372-84. [PMID: 26824929 DOI: 10.3390/diagnostics3040372] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
77 Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012;37:121-7. [PMID: 22228332 DOI: 10.1097/RLU.0b013e3182393599] [Cited by in Crossref: 70] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
78 Vanhove K, Graulus GJ, Mesotten L, Thomeer M, Derveaux E, Noben JP, Guedens W, Adriaensens P. The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism. Front Oncol 2019;9:1215. [PMID: 31803611 DOI: 10.3389/fonc.2019.01215] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
79 Hou S, Lin X, Wang S, Shen Y, Meng Z, Jia Q, Tan J. Combination of positron emission tomography/computed tomography and chest thin-layer high-resolution computed tomography for evaluation of pulmonary nodules: Correlation with imaging features, maximum standardized uptake value, and pathology. Medicine (Baltimore) 2018;97:e11640. [PMID: 30075545 DOI: 10.1097/MD.0000000000011640] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
80 Antonsen SL, Loft A, Fisker R, Nielsen AL, Andersen ES, Høgdall E, Tabor A, Jochumsen K, Fagö-olsen CL, Asmussen J, Berthelsen AK, Christensen IJ, Høgdall C. SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients. Gynecologic Oncology 2013;129:298-303. [DOI: 10.1016/j.ygyno.2013.01.019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
81 Kim SL, Kim EM, Cheong SJ, Lee CM, Kim DW, Jeong HJ, Lim ST, Sohn MH, Yim CY. The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells. Nucl Med Biol 2009;36:427-33. [PMID: 19423011 DOI: 10.1016/j.nucmedbio.2009.01.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
82 de Geus-oei L, Krieken JHJV, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, Boerman OC, Oyen WJ. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79-87. [DOI: 10.1016/j.lungcan.2006.08.018] [Cited by in Crossref: 133] [Cited by in F6Publishing: 128] [Article Influence: 9.5] [Reference Citation Analysis]
83 Kaira K, Ohde Y, Okumura T, Nakagawa K, Takahashi T, Murakami H, Naito T, Tsuya A, Nakamura Y, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. RETRACTED ARTICLE: Relationship between 18F-FDG uptake on PET and various biologic molecular markers in benign pulmonary lesion: comparison with primary lung cancer. Ann Nucl Med 2012;26:288-288. [DOI: 10.1007/s12149-011-0501-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
84 Chen SW, Lin YC, Chen RY, Hsieh TC, Yen KY, Liang JA, Yang SN, Wang YC, Chen YH, Chow NH, Kao CH. Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer. Eur J Nucl Med Mol Imaging 2016;43:2343-52. [PMID: 27311919 DOI: 10.1007/s00259-016-3436-z] [Reference Citation Analysis]
85 Kim MH, Ko SH, Bae JS, Lee SH, Jung CK, Lim DJ, Baek KH, Kim SH, Lee JM, Kang MI, Cha BY. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma. Thyroid 2013;23:1452-60. [PMID: 23688271 DOI: 10.1089/thy.2013.0051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
86 Márquez Rodas I, de Miguel Díez J, Luis Álvarez-sala J. La tomografía por emisión de positrones en el estudio del nódulo pulmonar solitario. Archivos de Bronconeumología 2008;44:493-8. [DOI: 10.1016/s0300-2896(08)72120-3] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
87 Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. European Journal of Cancer 2012;48:1244-54. [DOI: 10.1016/j.ejca.2012.01.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
88 Huang CT, Yen RF, Cheng MF, Hsu YC, Wei PF, Tsai YJ, Tsai MF, Shih JY, Yang CH, Yang PC. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol 2010;27:9-15. [PMID: 19130320 DOI: 10.1007/s12032-008-9160-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
89 Paull DE, Moezzi J, Katz N, Little AG, Adebonojo SA. Positron Emission Tomography in Well Differentiated Fetal Adenocarcinoma of the Lung: . Clinical Nuclear Medicine 2006;31:213-4. [DOI: 10.1097/01.rlu.0000204131.93846.39] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
90 Surov A, Meyer HJ, Wienke A. Standardized Uptake Values Derived from 18F-FDG PET May Predict Lung Cancer Microvessel Density and Expression of KI 67, VEGF, and HIF-1α but Not Expression of Cyclin D1, PCNA, EGFR, PD L1, and p53. Contrast Media Mol Imaging 2018;2018:9257929. [PMID: 29983647 DOI: 10.1155/2018/9257929] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
91 Yao G, Zhou Y, Gu Y, Wang Z, Yang M, Sun J, Luo Q, Zhao H. Value of combining PET/CT and clinicopathological features in predicting EGFR mutation in Lung Adenocarcinoma with Bone Metastasis. J Cancer 2020;11:5511-7. [PMID: 32742498 DOI: 10.7150/jca.46414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
92 Shimizu K, Hirami Y, Saisho S, Yukawa T, Maeda A, Yasuda K, Nakata M. Maximal Standardized Uptake Value on FDG-PET Is Correlated With Cyclooxygenase-2 Expression in Patients With Lung Adenocarcinoma. The Annals of Thoracic Surgery 2012;93:398-403. [DOI: 10.1016/j.athoracsur.2011.10.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
93 Devic S. Warburg Effect - a Consequence or the Cause of Carcinogenesis? J Cancer 2016;7:817-22. [PMID: 27162540 DOI: 10.7150/jca.14274] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
94 Haberkorn U. Positron emission tomography (PET) of non-small cell lung cancer. Lung Cancer 2001;34:S115-21. [DOI: 10.1016/s0169-5002(01)00351-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
95 Lv M, Fan YB, Zhao YJ, Wang TY, Wu GP. Expression and clinical significance of glucose transporter 1 mRNA in bronchial brushing liquid-based cytology specimens from patients with and without lung cancer. Cytopathology 2012;23:108-13. [PMID: 21294792 DOI: 10.1111/j.1365-2303.2010.00846.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
96 Motiei M, Dreifuss T, Betzer O, Panet H, Popovtzer A, Santana J, Abourbeh G, Mishani E, Popovtzer R. Differentiating Between Cancer and Inflammation: A Metabolic-Based Method for Functional Computed Tomography Imaging. ACS Nano 2016;10:3469-77. [PMID: 26886076 DOI: 10.1021/acsnano.5b07576] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
97 Nair VS, Krupitskaya Y, Gould MK. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol 2009;4:1473-9. [PMID: 19887967 DOI: 10.1097/JTO.0b013e3181bccbc6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
98 Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, Boellaard R, van Lanschot JJ, Molthoff CF. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol. 2008;134:227-236. [PMID: 17653575 DOI: 10.1007/s00432-007-0275-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
99 Bollineni VR, Wiegman EM, Pruim J, Groen HJ, Langendijk JA. Hypoxia imaging using Positron Emission Tomography in non-small cell lung cancer: implications for radiotherapy. Cancer Treat Rev 2012;38:1027-32. [PMID: 22560366 DOI: 10.1016/j.ctrv.2012.04.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
100 Ercelep O, Alan O, Telli TA, Tuylu TB, Arıkan R, Demircan NC, Simsek ET, Babacan NA, Kaya S, Dane F, Bozkurtlar E, Ones T, Lacin T, Yumuk PF. Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma. Tumori 2021;107:231-7. [PMID: 32878562 DOI: 10.1177/0300891620950475] [Reference Citation Analysis]
101 Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004;25:11-7. [PMID: 15061260 DOI: 10.1097/00006231-200401000-00003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
102 Tsujikawa T, Okazawa H, Tsuchida T, Demura Y, Imamura Y, Fujibayashi Y. A 18F-FDG-positive, 67Ga-negative, and transferrin receptor expression-negative patient with diffuse large B-cell lymphoma. Ann Nucl Med 2007;21:375-8. [DOI: 10.1007/s12149-007-0037-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
103 Li S, Guo W, Ren G, Huang G, Chen T, Song S. Expression of Glut-1 in primary and recurrent head and neck squamous cell carcinomas, and compared with 2-[18F]fluoro-2-deoxy-D-glucose accumulation in positron emission tomography. British Journal of Oral and Maxillofacial Surgery 2008;46:180-6. [DOI: 10.1016/j.bjoms.2007.11.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
104 Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Serizawa M, Koh Y, Hanaoka H, Tominaga H, Oriuchi N, Kondo H, Nakajima T, Yamamoto N. Biologic Correlation of 2-[ 18 F]-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors. JCO 2010;28:3746-53. [DOI: 10.1200/jco.2009.27.4662] [Cited by in Crossref: 102] [Cited by in F6Publishing: 44] [Article Influence: 9.3] [Reference Citation Analysis]
105 Suzawa N, Ito M, Qiao S, Uchida K, Takao M, Yamada T, Takeda K, Murashima S. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Lung Cancer 2011;72:191-8. [DOI: 10.1016/j.lungcan.2010.08.017] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
106 Zhan P, Wang J, Lv X, Wang Q, Qiu L, Lin X, Yu L, Song Y. Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis. Journal of Thoracic Oncology 2009;4:1094-103. [DOI: 10.1097/jto.0b013e3181a97e31] [Cited by in Crossref: 126] [Cited by in F6Publishing: 66] [Article Influence: 10.5] [Reference Citation Analysis]
107 Lv M, Cha N, Zou YF, Leng JH, Hao YY, Wang S. The significance of detecting glucose transporter 1 and calretinin in serous effusions to differentiate between carcinoma cells and reactive mesothelial cells. Diagn Cytopathol 2021;49:811-6. [PMID: 33818924 DOI: 10.1002/dc.24745] [Reference Citation Analysis]
108 Kwon SY, Min JJ, Song HC, Choi C, Na KJ, Bom HS. Impact of Lymphoid Follicles and Histiocytes on the False-Positive FDG Uptake of Lymph Nodes in Non-Small Cell Lung Cancer. Nucl Med Mol Imaging 2011;45:185-91. [PMID: 24900002 DOI: 10.1007/s13139-011-0085-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
109 Shim HK, Lee WW, Park SY, Kim H, So Y, Kim SE. Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas. Nuclear Medicine and Biology 2009;36:191-7. [DOI: 10.1016/j.nucmedbio.2008.11.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
110 Eriguchi D, Shimada Y, Imai K, Furumoto H, Okano T, Masuno R, Matsubayashi J, Kajiwara N, Ohira T, Ikeda N. Predictive accuracy of lepidic growth subtypes in early-stage adenocarcinoma of the lung by quantitative CT histogram and FDG-PET. Lung Cancer 2018;125:14-21. [PMID: 30429012 DOI: 10.1016/j.lungcan.2018.08.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
111 Meyer HJ, Gundermann P, Surov A. Associations between FDG-PET and Ki 67-index in head and neck cancer: A meta-analysis. Medicine (Baltimore) 2019;98:e17472. [PMID: 31577779 DOI: 10.1097/MD.0000000000017472] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Lu P, Yu L, Li Y, Sun Y. A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer. Nuclear Medicine Communications 2010;31:646-51. [DOI: 10.1097/mnm.0b013e328339bddb] [Cited by in Crossref: 11] [Article Influence: 1.0] [Reference Citation Analysis]
113 Basu S, Hess S, Nielsen Braad P, Olsen BB, Inglev S, Høilund-carlsen PF. The Basic Principles of FDG-PET/CT Imaging. PET Clinics 2014;9:355-70. [DOI: 10.1016/j.cpet.2014.07.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
114 Chen JQ, Russo J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim Biophys Acta. 2012;1826:370-384. [PMID: 22750268 DOI: 10.1016/j.bbcan.2012.06.004] [Cited by in Crossref: 60] [Cited by in F6Publishing: 125] [Article Influence: 6.7] [Reference Citation Analysis]
115 Tohma T, Okazumi S, Makino H, Cho A, Mochizuki R, Shuto K, Kudo H, Matsubara K, Gunji H, Matsubara H. Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis. Dis Esophagus. 2005;18:185-189. [PMID: 16045581 DOI: 10.1111/j.1442-2050.2005.00489.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
116 Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654-662. [PMID: 15389572 DOI: 10.1002/jcp.20166] [Cited by in Crossref: 739] [Cited by in F6Publishing: 703] [Article Influence: 46.2] [Reference Citation Analysis]
117 Sugita S, Yamato M, Hatabu T, Kataoka Y. Involvement of cancer-derived EMT cells in the accumulation of 18F-fluorodeoxyglucose in the hypoxic cancer microenvironment. Sci Rep 2021;11:9668. [PMID: 33994540 DOI: 10.1038/s41598-021-88414-1] [Reference Citation Analysis]
118 Kang DY, Lee HW, Choi PJ, Lee KE, Roh MS. Sodium/iodide symporter expression in primary lung cancer and comparison with glucose transporter 1 expression. Pathol Int. 2009;59:73-79. [PMID: 19154259 DOI: 10.1111/j.1440-1827.2008.02331.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
119 Yamatani C, Maniwa T, Takahashi S, Isaka M, Ohde Y, Endo M, Nakajima T, Kondo H. Variation in 18F-FDG PET findings in a patient with synchronous multiple thymoma. Gen Thorac Cardiovasc Surg 2015;63:586-9. [DOI: 10.1007/s11748-013-0354-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
120 Lombardi AF, Wong JH, High R, Ma Y, Jerban S, Tang Q, Du J, Frost P, Pagel MD, Chang EY. AcidoCEST MRI Evaluates the Bone Microenvironment in Multiple Myeloma. Mol Imaging Biol 2021. [PMID: 33939066 DOI: 10.1007/s11307-021-01611-2] [Reference Citation Analysis]
121 Dreifuss T, Ben-Gal TS, Shamalov K, Weiss A, Jacob A, Sadan T, Motiei M, Popovtzer R. Uptake mechanism of metabolic-targeted gold nanoparticles. Nanomedicine (Lond) 2018;13:1535-49. [PMID: 30028251 DOI: 10.2217/nnm-2018-0022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
122 Meyer HJ, Wienke A, Surov A. Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-A systematic review and meta analysis. PLoS One 2019;14:e0217781. [PMID: 31206524 DOI: 10.1371/journal.pone.0217781] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
123 Usuda K, Sagawa M, Aikawa H, Ueno M, Tanaka M, Machida Y, Zhao XT, Ueda Y, Higashi K, Sakuma T. Correlation between glucose transporter-1 expression and 18F-fluoro-2-deoxyglucose uptake on positron emission tomography in lung cancer. Gen Thorac Cardiovasc Surg. 2010;58:405-410. [PMID: 20703861 DOI: 10.1007/s11748-010-0603-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
124 Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-87. [PMID: 11786564 DOI: 10.1200/JCO.2002.20.2.379] [Cited by in Crossref: 175] [Cited by in F6Publishing: 141] [Article Influence: 9.2] [Reference Citation Analysis]
125 Wiebe LI. PET radiopharmaceuticals for metabolic imaging in oncology. International Congress Series 2004;1264:53-76. [DOI: 10.1016/j.ics.2003.12.102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]